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Antitumor agentsAlmost all invasive cancers, regardless of tissue origin, are characterized by speciﬁc modiﬁcations of their
cellular energy metabolism. In fact, a strong predominance of aerobic glycolysis over oxidative phosphor-
ylation (Warburg effect) is usually associated with aggressive tumour phenotypes. This metabolic shift
offers a survival advantage to cancer cells, since they may continue to produce energy and anabolites
even when they are exposed to either transient or permanent hypoxic conditions. Moreover, it ensures
a high production rate of glycolysis intermediates, useful as building blocks for fast cell proliferation of
cancer cells. This peculiar metabolic proﬁle may constitute an ideal target for therapeutic interventions
that selectively hit cancer cells with minimal residual systemic toxicity. In this review we provide an
update about some of the most recent advances in the discovery of new bioactive molecules that are able
to interfere with cancer glycolysis.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Deregulation of cellular energetics is emerging as one of the
most important hallmarks of cancer.1 Among the many adjust-
ments of the metabolic pathways that are found in tumor cells, a
key role is played by an enhanced aerobic glycolysis followed by
lactic fermentation, which is also known as the Warburg effect.2
In fact, normal cells generally transform glucose into carbonic
anhydride under aerobic conditions, by means of oxidative
phosphorylation (OXPHOS). On the contrary, invasive cancer cells
mostly produce lactate, even in the presence of sufﬁcient levels
of oxygen, although this glycolytic pathway turns out to be less
efﬁcient than OXPHOS in producing ATP units. This apparently
counterproductive behavior of cancer cells actually constitutes a
survival advantage in rapidly proliferating cells, since it make them
insensitive to transient or permanent hypoxic conditions, it con-
tributes to the production of nucleosides and aminoacids, and,
thanks to the enhanced glucose uptake occurring in cancer tissues,
constitutes a very rapid way to produce energy. Furthermore, lac-
tate is not just a waste product of this process; on the contrary, it
promotes tumor invasion by favoring cell migration, angiogenesis,
immune escape and radioresistance.3 This redirection of glucose
metabolism is promoted by the overexpression of the many effec-
tors of the glycolytic pathway, consisting of speciﬁc membrane
transporters of glucose (GLUTs) and lactate (MCTs), as well as of
all the enzymes responsible for the promotion of each single stepof the cascade involved in the transformation of glucose into lactic
acid. This type of modiﬁcations raised questions about the possibil-
ity that cancer is a metabolic disease, which may be actually initi-
ated by an impairment of some of the mitochondrial functions.4
Regardless its origin, the metabolic shift present in most invasive
cancer tissues may lead to the development of newmeans to selec-
tively counteract cancer progression, without causing signiﬁcant
damages to healthy cells.5 Several reviews dealing with com-
pounds that target cancer metabolism have been published in
the near past.6–9 We herein provide an update of the most signiﬁ-
cant recent advances in the development of ‘antiglycolytic’
anticancer agents, which have been classiﬁed on the basis of their
principal targets.
Glucose transporters (GLUTs): Glucose transporters (GLUTs) con-
stitute a family of proteins that regulate the transport of glucose
across the hydrophobic cell membranes. As of today 14 isoforms
of the GLUT genes have been identiﬁed, which show similar struc-
tural architecture but different cellular and sub-cellular localiza-
tion, kinetic properties and afﬁnity for glucose and other hexoses.
Different GLUTs have been found to be overexpressed in a wide
variety of cancer types, and their level of expression often corre-
lates with the metastatic potential and worse prognosis of the
tumor.10 In particular, over the past few years GLUT1 has been
regarded as a potential target in oncology drug discovery. Very
recently, a human GLUT1 crystal structure was obtained, and this
achievement will surely be helpful in the discovery of new GLUT1
inhibitors as anti-cancer agents.11
4916 C. Granchi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4915–4925A series of polyphenolic esters were found to inhibit glucose
transport through the cell membrane, and to exert a certain
antiproliferative activity in the H1299 lung cancer cell line.12,13
The initial development of this class led to WZB117 1 (Fig. 1),
which showed 93% inhibition in a standard glucose uptake assay
and 41% inhibition of cancer cell growth rate (IC50 = 10 lM in cell
viability assays) in lung cancer cells, with a more pronounced anti-
proliferative effect under hypoxic conditions. Compound 1 proved
to exert its antiproliferative activity selectively on tumor cells, as
demonstrated by growth inhibition in lung (A549) and breast
(MCF7) cancer cells lines, without being effective on their corre-
sponding non-tumorigenic counterparts (NL20 and MCF12A,
respectively). In an A549 xenograft model of human lung cancer
WZB117, dosed intraperitoneally daily at 10 mg/kg, induced more
than 70% reduction of tumor volume without any signiﬁcant side
effects, with the exception of a mild and reversible hyperglycemia.
Further studies using human red blood cells, which uniquely
express GLUT1 as the glucose transporter, conﬁrmed that
WZB117 speciﬁcally targets GLUT1 isoform in the inhibition of
glucose transport. Co-administration of WZB117 with the
mitochondrial inhibitor oligomycin led to a synergistic reduction
of proliferation of A549 lung cancer cells. At a dose (50 nmol/L)
at which oligomicin alone does not exert signiﬁcant antiprolifera-
tive effect, co-administration with WZB117 sensitizes cancer cellsWZB117
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Figure 1. Structures oto GLUT inhibition and induces cell cycle arrest, senescence and,
ﬁnally, necrosis.14
Natural compound (+)-cryptocaryone 2 (Fig. 1) has been
recently identiﬁed among the components of an extract isolated
from the leaves and twigs of Cryptocarya rubra, a tropical plant
belonging to the Lauraceae family.15 This extract was found to be
cytotoxic on HT-29 human colon cancer cells, as widely reported
in the literature, where there are many evidences of the cytotoxic-
ity of this dihydrochalcone on cancer cell lines, such as its ability to
induce apoptosis through activation of caspases in prostate
tumor.16,17 Consistent with previous data, compound 2 showed
an IC50 value of 0.32 lM on HT-29 cells, and was found to cause
a signiﬁcant reduction of the uptake of glucose, implying that its
anti-proliferative activity could be ascribed, at least in part, to
GLUT inhibition.
Some members of a class of oxime derivatives, which had been
previously designed as estrogen receptor (ER) ligands18 revealed to
be active as GLUT1-inhibitors. These compounds show some com-
mon pharmacophoric similarities with WZB117-like inhibitors,
mainly consisting in the presence of similarly-spaced peripheral
‘phenol-type’ OH groups.19 Aldoximes 3 and 4 (Fig. 1), which differ
only for a ﬂuorine atom in meta position of the distal phenyl ring,
displayed IC50 values of 8.5 lM (3) and 23.4 lM (4) in the glucose
uptake assay, whereas ketoximes 5 and 6 (Fig. 1), which, similarlyO
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C. Granchi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4915–4925 4917to the other pair of compounds, differ only for the substitution on
the distal phenyl, showed IC50 values of 15.5 and 10.6 lM,
respectively, with inhibition potencies generally comparable to
that of WZB117 (IC50 = 10.9 lM). Compounds 3–6, which are
devoid of signiﬁcant binding afﬁnity for the estrogen receptors,18
demonstrated good potencies against H1299 lung cancer cells in
antiproliferative assays, with IC50 values ranging from 14 to
39 lM. Ketoxime 6 was analyzed, as a representative member of
this class, by modeling studies in a computational model of GLUT1,
which identiﬁed the intracellular region of the transporter as the
most likely binding site of these compounds.
Thiazolidinediones 7 and 8 (Fig. 1) were developed following
the observation that a peroxisome proliferator-activated receptor
c (PPARc) agonist exerted part of its action through inhibition of
glucose transport.20 Compound 7 exhibited an excellent suppres-
sion of glucose uptake (IC50 = 2.5 lM) in LNCaP prostate cancer
cells. This activity led to an efﬁcient antiproliferative activity on
the same cell line, with no evident toxicity on healthy prostate
and mammary epithelial cells. The GLUT-isoform selectivity of
compound 7 was conﬁrmed by transfecting LNCaP cells with the
main GLUT isoforms. These experiments showed that the GLUT1-
mediated glucose internalization was inhibited by 7 with an IC50
value very similar to that determined for the suppression of glu-
cose uptake (2 lM) in the original cells, whereas its inhibition
was weaker in the cells that were transfected with GLUT3, GLUT4
or GLUT 9 (>5 lM), thus conﬁrming GLUT1 as the preferential tar-
get of inhibitor 7. Modeling studies conﬁrmed these experimental
results, suggesting the binding of 7 in the intermembrane channel
of the protein, mostly through electrostatic and p–p stacking inter-
actions, which constitutes a distinct site of interaction from that of
glucose. Further studies were conducted to understand the molec-
ular mechanisms at the base of the anti-tumour activity and it was
demonstrated that 7 triggers a series of energy restriction-associ-
ated cellular responses, which ﬁnally culminate in apoptotic cell
death. Thiazolidinedione 8, displaying a slightly lower activity
(IC50 = 6 lM in glucose uptake inhibition, IC50 = 5 lM in GLUT1
inhibition) than that of 7, was further examined in in vitro exper-
iments in association with gemcitabine. Compound 8 restored the
sensitivity of drug-resistant pancreatic cancer cells to gemcitabine,
by counteracting the activation and the expression of genes
involved in DNA repair as response to treatment with this drug
and consequently enhancing DNA damage and promoting cell
death. In vivo, oral administration of 8 in combination with gem-
citabine therapy demonstrated a signiﬁcant level of synergism,
without any relevant toxicity in the treated mice.21
Methylxanthines are a family of natural compounds with a vast
variety of physiological effects. In particular caffeine (1,3,7-trim-
ethylxanthine 9, Fig. 1), theophylline (1,3-dimethylxanthine 10,
Fig. 1) and the synthetic methylxanthine pentoxifylline
[1-(5-oxohexil)-3,7-dimethylxanthine 11, Fig. 1] are also known
to be inhibitors of glucose transport. Over the past few years, the
binding of these inhibitors to GLUT1 was better characterized in
human red blood cells. Compounds 9, 10 and 11 were able to dis-
place the GLUT1 inhibitor cytochalasin B from the protein, thus
conﬁrming their direct interaction with GLUT1. Moreover, kinetic
assays revealed that all of them interact with the protein in a spe-
ciﬁc binding site on the exofacial surface of the transporter, which
is close, but distinct from D-glucose binding site.22
A similar study concerned resveratrol 12 (Fig. 1), a natural phy-
toalexin whose inﬂuence on glucose metabolism is widely
reported in literature.23–25 Resveratrol was able to block glucose
uptake and hinder glucose accumulation in HL-60 and U-937
leukemic cells, two cell lines that both express mainly the GLUT1
isoform. In red blood cells resveratrol displaced the previously
bound cytochalasin B from the protein, revealing a direct interac-
tion that was localized on the endofacial site of the transporter.26STF-31, a GLUT inhibitor discovered by Giaccia and co-work-
ers,27,28 has been elaborated to obtain afﬁnity chromatography
reagents for target identiﬁcation.29 Starting from STF-31 chemical
structure, a long poly-ether amino-alkyl chain was introduced in
the para position of the phenyl sulfonamide terminal moiety to
obtain compound 13 (Fig. 1). The design of this compound was dic-
tated by the fact that the transporter presents a steric tolerance at
the 4-position of the phenyl group of STF-31, which is oriented
toward the intracellular entrance of the channel. Compound 13
was tested in a growth inhibition assay on the glycolysis-
dependent von Hippel–Lindau-deﬁcient renal carcinoma cells
(VHL-deﬁcient RCC4), displaying an IC50 value of 7.9 lM, with a
good level of selectivity compared to VHL-positive cell line (IC50
>40 lM). Thus, it was conjugated to resins and used for afﬁnity
chromatography in VHL-deﬁcient RCC4 lysates. The selective
retention of GLUT1 protein by the 13-conjugated resin reagent con-
ﬁrmed that GLUT1 is the target of these 3-pyridylphenylsulfonyl
benzamide derivatives.
Hexokinase (HK): The ﬁrst step in glycolysis is catalyzed by
hexokinase (HK) and consists in the transfer of one phosphate
group from ATP to glucose, yielding glucose-6-phosphate. Isoform
2 of hexokinase (HK2) is considered to play two crucial roles in the
reprogrammed glycolytic metabolism of tumor cells. First, HK2 up-
regulation results in increased glycolysis rates and, second, associ-
ation of HK2 in a complex with a voltage dependent anion channel
(VDAC) on the external mitochondrial membrane contributes to
inhibition of apoptosis through block of cytochrome c release from
mitochondria. Moreover, HK2-bound to mitochondria is insensi-
tive to product inhibition and gains preferential access to newly
synthesized ATP for phosphorylating glucose.30 Despite these ﬁnd-
ings indicate HK2 as a very attractive anticancer target, there
remain remarkable few reports on drug discovery programs aimed
to the identiﬁcation of selective HK2 inhibitors. TransTech Pharma
claimed the identiﬁcation of potent human HK1 and HK2 inhibitors
that also inhibit tumor cell growth (ovarian, lung, pancreas) and
induce apoptosis in vitro, but no precise ﬁgures nor chemical struc-
tures have been disclosed so far.31 Glaxo Wellcome Manufacturing
Pte Ltd claimed a series of glucosamine derivatives,32 several of
which, including 14 (Fig. 2), exhibited pIC50 values higher than
6.5 for HK2 inhibition. More recently a series of spirooxindole
derivatives, such as 15 (Fig. 2), displaying micromolar potencies
in HK2-inhibition assays, were discovered by scientists of the
Okinawa Institute of Science And Technology.33
In addition, HK2 inhibitory activity was demonstrated for anti-
cancer agents with complex mechanism of action, such as: (1)
alkylating agent and glycolysis inhibitor 3-bromo-pyruvate (16,
Fig. 2),30 which has been recently granted FDA orphan drug desig-
nation for liver cancer; (2) copper-phenanthroline complex
Casiopeina IIgly (17, Fig. 2);34 (3) antidiabetic drug metformin
(18, Fig. 2),35 whose antitumoral properties are under intensive
investigation. Thus, HK2 inhibition likely contributes to the multi-
ple mechanisms underlying the anticancer action of these agents.
Phosphofructokinase (PFK): Isoform 1 of phosphofructokinase
(PFK1) catalyzes one of the most critical steps of glycolysis, the
conversion of fructose-6-phosphate and ATP to fructose-1,6-bis-
phosphate and ADP. PFK1 activity is enhanced by the allosteric
activator fructose-2,6-bisphosphate, whose production is regu-
lated by phosphofructokinase 2, also named fructose-2,6-bisphos-
phatase (PFK2/FBPase), due to its dual function as a kinase and as a
phosphatase. In fact PFK2/FBPase controls both the production of
fructose-2,6-bisphosphatase from fructose-6-phosphate and its
reverse hydrolytic reaction. Among the four isoenzymes belonging
to the PFK2/FBPase family, PFKFB3 is overexpressed in hypoxic
tumors under HIF-1a regulation and, thanks to its increased kinase
activity, PFKFB3 is the enzyme that most likely contributes to the
high glycolytic activity in these tumors.36
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Figure 2. Structures of HK inhibitors.
4918 C. Granchi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4915–4925The initial reference compound for PFKFB3-inhibition, 1,3-dia-
rylpropenone 3PO, was discovered in the group of Dr. Chesney
through computational modeling and virtual screening of chemi-
cal databases.37 The optimization of this class led ﬁrstly to
PFK15 19 (Fig. 3),38 which showed increased potency for the inhi-
bition of the recombinant human enzyme (IC50 = 207 nM vs
22.9 lM of 3PO), and high selectivity for PFKFB3 when tested in
a wide panel of different kinases. Similarly, PFK15 resulted to be
more cytotoxic in H522 lung adenocarcinoma and Jurkat T-cell
leukemia cells. Fructose-2,6-bisphosphatase, glucose uptake, and
ATP levels were signiﬁcantly reduced upon treatment with
PFK15, leading to cell death by apoptosis. Moreover, in vivo
PFK15 demonstrated improved pharmacokinetic properties, and
induced tumor growth inhibition in three human xenograft mod-
els (colon adenocarcinoma CT26, U-87 MG glioblastoma, and BX-
PC3 pancreatic adenocarcinoma) at a well-tolerated dose (25 mg/
kg ip every 3 days  4). Further optimization led to PFK158
(structure not disclosed), which was reported to be efﬁcacious
(approximately 80% growth inhibition) in several mouse models
on human-derived tumors, and well tolerated in rats and dogs.
PFK158 in combination with vemurafenib signiﬁcantly increased
the apoptotic death of several melanoma cell lines, in vitro. In
March 2014, a phase I trial with PFK158 was initiated in patients
with advanced solid malignancies.19
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Figure 3. Structures oA series of aminofurazan-triazoles was discovered by virtual
screening of commercially available libraries of compounds, and,
to the best of our knowledge, they are the ﬁrst class of structurally
related compounds comprising both activators and inhibitors of
PFKFB3.39 Compound 20 in Figure 3 is the most potent PFKFB3
inhibitor of this series, by reducing the PFKFB activity in enzymatic
assays (although complete inhibition was not reached even at the
highest tested concentration of 100 lM) and by decreasing the gly-
colytic ﬂux in rat muscle cell lysates at the concentration of 3 lM.
The predicted binding mode of the bulky aminofurazan-triazole
moiety reveals a network of hydrogen bonds with the phosphate
binding pockets, that are present in both the kinase and the phos-
phatase sites. Considering that compound 20 behaves as an inhib-
itor, it should bind with higher afﬁnity in the kinase site of the
enzyme, where electron-rich heterocyclic nitrogen and oxygen
atoms of the furazan and triazole rings, as well as the oxygen car-
bonyl atom of the hydrazide group, interact with arginine residues.
The afﬁnity to the kinase site is also given by the para-tolyl tail,
which occupies a small hydrophobic pocket that cannot accommo-
date the bulky polar substituents generally present in the activator
molecules. Compound 20 reduced the viability of a panel of cancer
cells (GI50 = 16–22 lM), but poor pharmaceutical properties, likely
linked to high molecular weight and large polar surface area,
prevented its further development.O
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C. Granchi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4915–4925 4919A recent high-throughput screen produced 5-triazolo-2-arylpy-
ridazinone 21 (Fig. 3) as a fairly potent PFKFB3 inhibitor
(IC50 = 7.4 lM), but unable to inhibit glycolysis in vitro at non-toxic
concentrations.40 Subsequent structural modiﬁcations failed to sig-
niﬁcantly improve the inhibitory potency of this initial hit.
Phosphoglycerate mutase (PGM): Phosphoglycerate mutase
(PGM) catalyzes the reversible conversion of 3-phosphoglycerate
to 2-phosphoglycerate. In mammals, PGM exists as two homodi-
mers consisting of two muscle-type monomers (PGM-MM), two
brain-type monomers (PGM-BB), or as a heterodimer (PGM-MB).
One of the homodimers, PGM-BB is also named PGM1 in humans
and is ubiquitously expressed. It has been reported that PGM1 is
usually up-regulated in human cancer tissues and plays an
important, albeit not yet fully investigated role in cancer cell
metabolism.41 Only a few studies have been so far dedicated to
the discovery of PGM1 inhibitors. One of them was focused on
dihydroxyanthraquinone derivatives, which were developed start-
ing from dye Alizarin, and led to the identiﬁcation of PGM1-inhib-
itor PGMI-004A 22 (Fig. 4).42 In enzymatic assays compound 22
displayed a PGM1-inhibition activity in the low micromolar range
(IC50 = 13.1 lM, Ki = 3.91 lM), and turned out to be more cytotoxic
than parent compound Alizarin in cancer cells, possibly due to a
higher cell membrane permeability conferred by the hydrophobic
4-(triﬂuoromethyl)phenylaminosulfonyl substituent. Thermal shift
assays revealed a direct binding of 22 to PGM1 and kinetic studies
highlighted an allosteric interaction with this enzyme. Treatment
of human non-small cell lung carcinoma H1299 cells with PGM1-
004A decreased lactate production and altered both the glycolytic
metabolism and the anabolic synthesis. Moreover, this compound
reduced cell proliferation in H1299 cells and in several other can-
cer cell lines, with minimal toxicity to normal healthy cells. In vivo,
100 mg/kg/day of 22 resulted to be a well-tolerated dose that
caused a signiﬁcant decrease of tumor growth and size in treated
animals.
Enolase (ENO): Enolase is the glycolytic enzyme responsible for
the conversion of 2-phosphoglycerate to 2-phosphoenolpyruvate.
Increased expression of the alpha-enolase isoform (ENO1) has been
detected in several tumors and recently Muller et al. have validated
enolase as an anti-cancer target. ENO1 gene is deleted in glioblas-
toma and this lack is counterbalanced by the expression of the iso-
form ENO2, however if ENO2 was selectively blocked by shRNA the
result was inhibition of growth and survival of the ENO1-deleted
tumour cells. Similarly, ENO1-deleted cells proved to be more sen-
sitive to the cytotoxic action of phosphonoaceto-hydroxamate, a
substrate analogue enolase inhibitor.43
Until recently, ENO inhibitors had only been found among
substrate analogues. Jung et al. reported tri-substituted triazine
ENOblock 23 (Fig. 5) as the ﬁrst non-substrate analogue ENO1
inhibitor that directly binds the enzyme (IC50 = 0.576 lM), as
conﬁrmed by afﬁnity chromatography experiments.44 ENOblock
decreases cell viability under hypoxic conditions, while under nor-
moxia it reduces cancer cell invasion/migration at concentrations
that do not induce cytotoxicity, and synergizes with microtubule-
destabilizing drugs. Indeed, in a zebraﬁsh cancer xenograft model,22
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Figure 4. Structure of PGM inhibitor.23 was able to reduce cancer cell dissemination, thus conﬁrming
the great potential of ENO inhibitors as anti-metastatic agents.
Quite surprisingly, treatment with ENOblock 23 causes an increase
of the glucose uptake in liver cells, probably due to the down-
regulation of enzyme phosphoenolpyruvate carboxykinase, which
is involved in gluconeogenesis in hepatocytes. While these ﬁndings
open interesting perspectives for the development of ENO inhibi-
tors as antidiabetic agents, it still need to be further evaluated in
the context of anti-cancer drug development.
Pyruvate kinase (PK): Pyruvate kinase (PK) catalyzes the ﬁnal
rate-limiting step of glycolysis, which consists in the transfer of a
phosphate group from phosphoenolpyruvate (PEP) to ADP, to give
pyruvate and ATP. Isoform PKM2 may exist in both a high-activity
tetrameric and a low-activity dimeric form. Moreover, glycolytic
intermediate fructose-1,6-biphosphate and natural aminoacid ser-
ine are allosteric activators of PKM2. Increased levels of the less
active dimeric PKM2 lead to a decreased rate of glycolysis, and
an up-regulation of PKM2 has been observed in many tumor cells.
This fact may appear as paradoxical given the high rate of lactate
production in these cells. However, dimeric PKM2 may allow all
glycolytic intermediates above the PKM2 reaction to accumulate,
thereby providing a high level of metabolic precursors available
for the synthetic anabolic processes, in addition to energy produc-
tion. These ﬁndings explain why both inhibition and activation of
PKM2 have so far been considered as valid anticancer
approaches.45
A series of allosteric sulfonamido quinoline-based PKM2 activa-
tors has been widely explored by Agios Pharmaceuticals. The class
representative compound 24 (Fig. 6), which shows an AC50 of
0.017 lM, could be co-crystallized with PKM2 and conﬁrmed the
direct enzymatic activation induced by these compounds by bind-
ing to the protein in a pocket distinct from the substrate site.46
Moreover, 24 was able to activate the enzyme in cancer cells, with
AC50 of 45 nM in A549 lung adenocarcinoma cells. Interestingly, 24
was not effective in reducing the proliferation of cancer cells, but
when the experiments were repeated in the absence of serine,
PKM2 activation severely compromised cell viability. This result
revealed a link between glucose and aminoacid metabolism:
PKM2 activation deprives the serine biosynthetic pathway of gly-
colytic intermediates; hence cancer cells deeply depend on exoge-
nous serine to continue to grow, while the combination of serine
withdrawal and PKM2 activation leads to a complete block of cell
proliferation.47 Indeed, the PKM2 activator-induced serine auxot-
rophy was conﬁrmed by an increased expression of serine trans-
porters and enzymes involved in serine metabolism.
Recent patent applications ﬁled by Agios Pharmaceuticals on
these compounds claim their activity as activators of the erythro-
cyte-speciﬁc isozyme PKR,48 and their use for the treatment of
hereditary non-spherocytic hemolytic anemia, which is a genetic
disease that in very rare cases can manifest extreme severity and
for which no effective treatments are currently available. Indeed,
a Phase 1 clinical study of AG-348, a ﬁrst-in-class PKR activator,
24
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4920 C. Granchi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4915–4925for Pyruvate Kinase Deﬁciency is recently started. At this time it is
not clear if this strategy represents a repositioning of the class or
an accelerating factor for its development also in oncology.
Pyrazole-carboxamide SGI-10067 (25, Fig. 6) from Astex Phar-
maceuticals shows excellent activation potency both on the iso-
lated enzyme (AC50 = 11 nM) and in cell-based PKM2 activity
assays (AC50 = 0.22–0.26 lM).49 Similarly to 24, compound 25
inhibits cell proliferation in most cancer cell lines grown in media
lacking serine and, here again, this cytotoxic effect is rescued by
the addition of serine. SGI-10067 was well tolerated and showed
a modest tumor growth inhibition in the A549 lung xenograft
model.50
Benzimidazole-pyrimidone 26 (Fig. 6), discovered by Pﬁzer
scientists, showed good activation potency of PKM2 (AC50 = 0.159 lM)
and favorable ADME and pharmaceutical properties.51 The binding
mode of 26, as shown by crystallographic studies, places the
benzimidazole core in a peculiar pocket, which is different from
all the sites occupied by other previously reported PKM2 activa-
tors. The pyrimidinone ring of 26, placed on the other side of the
molecule, was found to be located between two phenylalanine
residues (Phe26) belonging to two different monomers of the
protein, with the consequent formation of strong p–p sandwich
interactions. Furthermore, compound 26 was found to be highly
selective for PKM2 when tested on a wide panel of kinases. In
cancer cell lines, compound 26 activated PKM2 (EC50 = 70 nM) by
inducing the formation of tetramers, but did not provoke any
change in oxygen consumption or lactate production, neither
signiﬁcantly inhibited cell proliferation.
Dynamix Pharmaceuticals developed a class of arylsulfonyl ind-
oline PKM2 activators, whose representative compound 27 (Fig. 6)
efﬁciently activates PKM2 (AC50 = 45 nM) with high selectivity for
isoform M2 versus the other PK isoforms. Also this activator binds
the enzyme at the interface of the two monomers of the protein
and makes a strong p–p stacking interaction with the two Phe26
residues of the protein.52
Lactate dehydrogenase (LDH): One of the most attractive glyco-
lytic targets is the enzyme lactate dehydrogenase (LDH), which
catalyzes the reversible conversion of pyruvate to lactate with
the simultaneous oxidation of the cofactor NADH to NAD+. The
human isoform LDH-A or LDH5 is composed of four A subunits
(LDH-A4) and is mainly expressed in liver and muscle. Several evi-
dences suggested that LDH-A, which is up-regulated in invasive
glycolytic cancers, plays a critical role in cell proliferation, allowing
the survival of tumors even in conditions of low oxygen concentra-
tion. Hence the inhibition of this enzyme is of great interest forcancer treatment. The safety of this approach can be hypothesized
considering that humans deprived of LDHA subunit by hereditary
deﬁciency lead an healthy life, suffering of myoglobinuria only
after an intense anaerobic exercise.53
A fragment-based approach accompanied by virtual screen of
commercially available databases was used by ARIAD Pharmaceu-
ticals as a strategy to discover some potent bifunctional LDH-A
inhibitors, which are able to bind both in the substrate and in
the cofactor binding sites of the enzyme. Among them, compound
28 (Fig. 7) showed an IC50 of 0.12 lM against LDH-A in enzymatic
assays. Crystallographic X-ray studies demonstrated that com-
pound 28 binds the nicotinamide pocket near the pyruvate biding
site with its 6-(3-ﬂuorophenyl)nicotinic acid terminal portion,
whereas the second opposite nicotinic acid part of 28 is located
in the adenosine site of cofactor NADH. The central hydroxylated
alkyl linker is located in a solvent-exposed region of the enzyme
and the OH groups establish a series of hydrogen bond interactions
with the protein. However, the presence of two carboxylate groups
negatively affects the cell membrane permeability of this molecule
in cellular assays, thus giving poor results in the reduction of cellu-
lar lactate production. Conversely, the removal of a single carbox-
ylate group (mono-acid compounds not shown) produced LDH-A
inhibition in cell-based assays, but with the drawback of losing a
great deal of activity on the isolated enzyme. 54
Ward et al. at AstraZeneca UK discovered one of the most potent
bifunctional LDH-A inhibitors by a fragment-based approach, the
diacid malonate-based compound 29 (Fig. 7). This inhibitor
showed an IC50 value of 0.27 lM and a Kd value of 0.008 lM in
the BIAcore binding afﬁnity assay but lacked of any cellular activ-
ity, probably because of the diacid functionality that hinders mem-
brane permeability.55
Screening of the Genentech/Roche corporate compound collec-
tion and lead optimization efforts produced two potent LDH-A
inhibitors: compound 30 possessing a 2-thio-6-oxo-1,6-dihydro-
pyrimidine structure and the 2-amino-5-aryl-pyrazine 31 (Fig. 7).
Both of them showed nearly identical IC50 values in the low micro-
molar range on LDH-A (IC50 = 0.48 and 0.50 lM, for compound 30
and 31, respectively), with good selectivities over the heart LDH
isoform (LDH1 or LDH-B) and the structurally similar enzyme
malate dehydrogenases 1 and 2 (MDH1 and MDH2). Crystal struc-
tures of some representative analogues of compounds 30 and 31
were obtained in the presence of NADH, thus suggesting that their
optimal binding requires the association with the cofactor. The
dihydropyrimidine-based inhibitors, such as 30, resulted to be
located in close proximity to residues involved in the catalytic
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C. Granchi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4915–4925 4921process, nevertheless they did not establish any direct interaction
with them, but only with different residues of the enzyme in an
adjacent region. Differently, pyrazine derivatives, such as 31, were
able to directly bind some catalytic residues. Anyway, both the
chemical classes formed strong interactions with the cofactor and
this observation was consistent with their great afﬁnity for the
enzyme when in the presence of NADH. Unfortunately, also Genen-
tech inhibitors were scarcely effective in reducing lactate produc-
tion in cancer cells.56,57 Recently, researchers at Genentech
disclosed the structure of GNE-140 (32, Fig. 7), a piperidindione
derivative inhibitor of LDH-A that was identiﬁed by the optimiza-
tion of a HTS hit. Compound 32 is a nanomolar inhibitor of LDH-A
(EC50 = 5 nM), which proved to be effective also in inhibiting
MiaPaCa-2 pancreatic cell proliferation with an EC50 of 0.25 lM.58
A similar class of LDH-A inhibitors characterized by a 3-hydroxy-
2-mercaptocyclohexenone scaffold, comprises the representative
compound 33 (Fig. 7), which showed an IC50 of 0.87 lM on
LDH-A, with an 8-fold selectivity for this isoform over LDH-B
(IC50 = 6.9 lM). Crystal structure analysis revealed that this inhibi-
tor binds to LDH-A only in the presence of the NADH cofactor. In
this situation the ionized enol moiety of the inhibitor interacts with
the catalytic Arg168 present in the enzyme active site, since it
behaved as a carboxylic acid mimic, while the other ketone
carbonyl group forms a hydrogen bonds with the side chains of
His192 and Asn137 of the catalytic site. Compound 33 possessesgood pharmacokinetic properties after oral administration in rats,
but similarly to the previously discovered compounds 30 and 31,
it was unable to reduce the production of lactate in cancer cell lines.59
Quinoline 3-sulfonamide 34 (Fig. 8) developed by GlaxoSmithK-
line is one of the most potent NADH-competitive LDH-A-inhibitor
discovered so far, with an IC50 of 2.6 nM (Ki = 4.8 nM), a sixteen-
fold selectivity over LDH-B (IC50 = 43 nM). Compound 34 inhibited
lactate production in several cancer cell lines. Detailed metabolic
studies were performed on the highly glycolytic Snu398 hepatocel-
lular carcinoma cells. In these cells, compound 34 reduced glucose
consumption, increased the rate of oxygen utilization, altered the
concentrations of many metabolic intermediates and, ﬁnally,
decreased cell survival by promoting apoptosis. Further studies
conﬁrmed that down-regulation of LDH-A activity by compound
34 in adenocarcinoma A549 cells reduced tumor formation.60 A
secondary effect of this quinoline-based inhibitor is the promotion
of PKM2 tetramer formation, contributing to the suppression of
tumorigenesis. However, compound 34 at high doses (10 lM) also
affects mitochondrial metabolism at, and this effect could contrib-
ute to the observed activity of the compound. The main limitation
of 34 are unfavorable pharmacokinetic properties, which hamper
its use in in vivo experiments.61
Recent studies of the chemical class of N-hydroxyindole-based
LDH-A-inhibitors produced several compounds that inhibit LDH-
A in the low micromolar range.62–66 It should be mentioned that
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4922 C. Granchi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4915–4925results from surface plasmon resonance experiments carried out
by Astra Zeneca on one of these compounds55 were ambiguous
and led the authors to hypothesize the occurrence of signiﬁcant
levels of nonspeciﬁc binding. Nevertheless, a recent study employ-
ing an external cavity laser (ECL) biosensor seems to indicate that
this type of inhibitors display a speciﬁc binding to LDH-A.67 A
recent development of this chemical class led to the discovery of
glucose-conjugated methyl ester 35 (Fig. 8), which inhibits LDH-
A with a Ki value of 37.8 lM and, therefore, it is a weaker inhibitor
than the N-OH analogue 36 (Fig. 8, Ki = 5.1 lM) on the isolated
enzyme.68,66 Nevertheless, compound 35 proved to be able to cross
the cell membrane very efﬁciently by means of GLUT transporters,
which actively promoted its uptake in cancer cells. In fact, the high
cell uptake of compound 35 was demonstrated by a quantitative
determination of its intracellular concentration. Furthermore, gly-
coconjugate 35 efﬁciently reduced lactate production in HeLa cells
and compromised cell proliferation in several cancer cell lines. On
the other hand aglycone 36 proved to be less efﬁcient than 35 in
cell-based assays, although it displayed enhanced properties of
enzyme inhibition potency (IC50 = 14.7 and 10.5 lM in NADH or
pyruvate-competition experiments respectively, IC50 = 29.0 and
73.4 lM for the corresponding acid), cell permeability, reduction
of lactate production and anti-proliferative activity, when com-
pared to its carboxylate analogs.62 In fact, the inhibition of LDH-
A activity by compound 36 increased the cellular NADH/NAD+ ratio
in p53-positive cells, and consequently it decreased the activity of
NAD(H)-dependent enzymes such as the deacetylase activity of sir-
tuin (SIRT1), leading to an increase in acetylated p53, a known tar-
get of SIRT1 deacetylation activity, and this resulted in induction of
apoptosis. The altered NADH/NAD+ balance also led to enhanced
sensitivity to redox-dependent anti-cancer agents, such as the qui-
none-based prodrug apaziquone, which synergistically induced
cell death together with compound 36.69 Moreover, methyl ester
36 exerted a synergistic cytotoxic action in pancreatic cancer cells
in combination with gemcitabine, when tested in hypoxic condi-
tions, and their association inhibited cell migration and invasion,
and induced apoptosis in these cell cultures.70
In the past few years, there has been a growing interest in the
discovery of natural products showing inhibitory properties
against LDH-A. In some cases only commonly used plant and
herbal extracts were identiﬁed by HTS procedure to be active onLDH-A.71 In other cases, a known a,b-unsaturated aldehyde, such
as 4-hydroxy-2-nonenal, which usually forms in meat products
by lipid peroxidation, was found to be able to bind to histidine
and cysteine residues of LDH-B.72 Unfortunately, no data related
to anticancer activities of these natural compounds were reported.
Manganese(II) complex 37 (Fig. 8) containing a di(pyridyl-
methyl)amine and a pyrrol-ketone moiety was developed as a dual
drug. In fact, it is a mimic of catalase, the enzyme catalyzing the
decomposition of hydrogen peroxide to water and oxygen, thus
being responsible for protecting cells from oxidative damage by
reactive oxygen species; additionally, this complex is also an
inhibitor of LDH-A. Kinetic studies were performed to evaluate
the LDH-A-inhibition potency of 37 (caution note: a rabbit LDH
isoform was used in this assay), revealing Ki values of 41.7 and
21.4 lM versus cofactor and substrate, respectively. Complex 37
displayed a good antiproliferative activity against HepG-2 cells,
and an additional inhibitory effect on hypoxia inducible factor 1a
(HIF-1a) expression.73
Monocarboxylate transporters (MCT): Monocarboxylate trans-
porters are responsible for the inwards and outwards cellular trans-
portation of monocarboxylate derivatives, such as lactate, pyruvate,
and ketone bodies. Among the 14 known human MCT homologue
members, the two isoforms MCT1 and MCT4 are the most fre-
quently overexpressed in many tumors and have been regarded
as viable anti-cancer targets. These two isoforms exert complemen-
tary roles in tumor cells: MCT1 (high afﬁnity for lactate) enables
lactate entry into oxidative/oxygenated cells that use it to produce
energy, whereas MCT4 (low afﬁnity for lactate) is mainly desig-
nated to export lactate and protons out of glycolytic cells, thus con-
tributing to maintain intracellular pH and avoid cytotoxic
accumulation of lactate. The therapeutic strategy of inhibiting
MCT4 is aimed to prevent lactate efﬂux from glycolytic cancer cells,
thus leading to intracellular acidiﬁcation and impairment of cell
proliferation. Inhibition of MCT1 primarily targets oxidative/oxy-
genated cancer cells that use lactate as a source of energy.
The N-methylbenzyl derivative 38 (Fig. 9) is a representative
compound of a series of 7-substituted carboxycoumarins MCT
inhibitors.74 Compound 38 inhibits lactate uptake with an IC50
value of 59 nM, measured by detecting the remaining lactate con-
centration in human cervix carcinoma SiHa cells (expressing
mainly MCT1) after 24 h of treatment.
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C. Granchi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4915–4925 4923Several additional evidences support the hypothesis that cellu-
lar activity of 38 is strictly due to inhibition of lactate uptake,
including: (i) induction of apoptosis only in cells growing in lac-
tate-containing medium, while cell viability is not affected when
glucose is available in the culture medium; (ii) comparative exper-
iments carried out on oxidative and glycolytic cancer cell lines,
which reveal that carboxycoumarin 38 interferes with lactate inﬂux
but not efﬂux. This behavior suggests a potential absence of side
effects in the tissues requiring the extrusion of lactate from cells,
such as muscles, brain and lymphocytes. Compound 38 was tested
in murine xenograft models, where it inhibited the growth of
tumors deriving from MCT-expressing cancers. Therapeutic syner-
gism between 38 and other drugs, such as cisplatin or 3-bromopy-
ruvate, resulted in a greater reduction of tumor volumes in animals
treatedwith combined therapies, compared to animals subjected to
single agent therapy. Moreover, compound 38 reduced tumor
relapse after cisplatin or 3-bromopyruvate treatment.75
AZD3965 (compound 39, Fig. 9) is a selective MCT1 inhibitor
(binding afﬁnity 1.6 nM), which is currently undergoing phase I
clinical trial in patients with advanced solid tumors or lym-
phoma.76 When tested on a panel of small cell lung cancer cell lines
assembled to reﬂect the mutations in TP53, RB1, and MYC family
genes that are common in SCLC, compound 39 induced a wide
range of responses, with general greater responses in hypoxic con-
ditions, where in some cases the treatment signiﬁcantly increased
intracellular lactate. COR-L103 (human small cell lung cancer cell
line) under hypoxic conditions turned out to be the most sensitive
among the cell lines tested. Consistently with the proposed mech-
anism of action, a higher dose of compound 39 was required to
inhibit MCT1 in engineered MCT1-overexpressed cells. In vivo,
AZD3965 (100 mg/kg bid  21dd) induced reduction of tumor
growth accompanied by high levels of intratumour lactate concen-
trations in a COR-L103 xenograft model.77,78
3-Bromopyruvate and 2-deoxyglucose: an update on two classical
‘multi-target’ antiglycolytic agents: The alkylating agent 3-bromopy-
ruvate 16 (3-BP, Fig. 10) is a halogenated pyruvate analogue usu-
ally regarded as a dual inhibitor, which primarily inhibits HK and
glyceraldeyde-3-phosphate dehydrogenase (GAPDH) by reacting
with the –SH nucleophile sites of these enzymes through the rapid
displacement of its bromo-leaving group.79,80 In particular, the
mitochondria-associated HK2 is speciﬁcally blocked by the forma-
tion of a pyruvinyl adduct after reaction with 3-BP at the surface ofBr
O
3-Bromopyruvate
O
HO
HO OH
OH
2-Deoxy-D-glucose
16 40
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O
Figure 10. Structures of mixed inhibitors 3-bromopyruvate 16 and 2-deoxyglucose
40.the outer mitochondrial membrane, leading to a severe depletion
of ATP after the inhibition of mitochondrial OXPHOS and, conse-
quently, to cell death.81 Due to the simple structure of 3-BP, it is
likely that this molecule interacts also with several other proteins,
such as the mitochondrial enzyme succinate dehydrogenase
and the glycolytic enzyme 3-phosphoglycerate kinase,82 as well
as H+-vacuolar ATPase,83 4-aminobutyrate aminotransferase,84
sarco/endoplasmic reticulum calcium ATPase type 1,85 and histone
deacetylase.86 All these interactions may contribute to the anti-
glycolytic effect and to the toxicity of this molecule. However, its
structural similarity to lactate enables this small molecule to
exploit MCTs for its cellular uptake, thus 3-BP selectively enters
and targets cancer cells, as demonstrated by a study in which
forced MCT1 expression in 3-BP-resistant cancer cells sensitized
tumor xenografts to 3-BP treatment in vivo.87 The overall toxicity
of this multifaceted molecule could be ascribed also to intracellular
reactive oxygen species (ROS) formation, leading to mitochondrial
dysregulation and a general oxidative stress that contributes to cell
death.88 This mechanism was proved in a study where D-amino
acid oxidase, a promising therapeutic target that induces oxidative
stress and apoptosis through ROS generation, was associated with
3-BP: this combined therapy sensitized glioma cells to 3-BP in vitro
and in a glioma tumour model in vivo.89 Despite the unspeciﬁc
mechanisms of action of 16, there are many ﬁndings in the litera-
ture showing that 3-BP completely eradicated advanced cancers
that are frequently refractory to standard therapeutics, without
recurrence, such as lymphoma and liver carcinoma.90–92 Many
studies were aimed at identifying combined treatments in order
to improve the cytotoxicity properties of 3-BP and, at the same
time, to reduce side effects. Among these efforts, synergistic effects
were obtained by the association between the propyl ester of 3-BP
and the inhibitor of mTOR rapamycin in lymphoma and leukemia
cells,93 the administration with geldanamycin, a speciﬁc inhibitor
of heat shock protein 90 in a pancreatic xenograft model94 and,
ﬁnally, 3-BP effectiveness in hepatocellular carcinoma was
improved by simultaneously inhibiting carbonic anhydrase-IX, a
zinc transmembrane metalloenzyme.95
2-Deoxy-D-glucose 40 (2-DG, Fig. 10) is a glucose analogue in
which the OH group in position 2 is replaced by an hydrogen atom.
2-DG competes with glucose for uptake and, once inside the cell, it
is phosphorylated by HK to phospho-2-DG. Now, phospho-2-DG
cannot be further metabolized by the following glycolytic enzyme
phosphoglucose isomerase and accumulates inside the cytoplasm
leading to the block of glycolysis. Although 2-DG alone has so far
shown limited anticancer affects in vivo, some promising results
were obtained by its association with standard chemotherapeutic
drugs, such as with adriamycin and paclitaxel in human osteosar-
coma and non-small cell lung cancers,96 with the microtubule dis-
ruptor 2-methoxyoestradiol-3,17-O,O-bis-sulfamate for breast and
prostate cancers,97 and with histone deacetylase inhibitors in glio-
blastoma cells.98 Recently, an antiproliferative effect on breast can-
cer stem cells was observed when administered alone or in
combination with doxorubicin.99 2-DG also sensitized gliomas
and other cancer cells to radiations, and it was well-tolerated by
the patients without provoking any relevant side effects.100,101 2-
DG toxicity is at least partially caused by interference withN-linked
glycosylation, a common oligosaccharide modiﬁcation of proteins,
leading to disruption in the folding of glycoproteins, endoplasmic
reticulum stress and apoptotic cell death.102 Interestingly, adminis-
tration of increasing concentrations of 2-DG in HeLa cells caused
signiﬁcant cytotoxicity, and when the same cell line was treated
with 2-DG before exposure to ionizing radiation, an effective
radiosensitization was observed. Tumor cells were protected by
these effects when 2-DG was co-incubated with thiol antioxidant
N-acetylcysteine, suggesting that alterations in thiol metabolism
by 2-DG contributed to cytotoxicity and radiosensitization.103
4924 C. Granchi et al. / Bioorg. Med. Chem. Lett. 24 (2014) 4915–4925After more than 50 years from the pioneering work of Warburg
demonstrating aberrant energy metabolism in cancer cells, several
lines of evidences have accumulated that indicate the enzymes of
the glycolytic pathway as viable targets for oncology, and several
drug discovery programs have been started to exploit them. Vari-
ous small molecules that are inhibitors of all the steps of the glyco-
lytic pathway have been identiﬁed, although for some of them a
note of caution should be sounded concerning their still incom-
plete level of characterization and the strong possibility that they
exert their cellular activity by hitting additional targets as well.
In general, many of the current glycolytic inhibitors showed only
moderate efﬁcacy when used as single agent, but in several cases
demonstrated high potential for combination with current thera-
pies. If this trend will be conﬁrmed, glycolytic inhibition could
become a valid strategy for sensitizing cancer cell to the action of
different anti-tumor agents, thus increasing their efﬁcacy and their
selectivity for tumors versus normal cells. Unfortunately, the inhi-
bition of lactate dehydrogenase, which seems to be the most
apparent target in this set because of its pivotal role in controlling
the switch from OXPHOS to glycolytic metabolism, turned out to
be an extremely tough objective and no inhibitors suitable for clin-
ical development have been so far identiﬁed. On the other hand,
ongoing clinical trials will help to assess the full potential of the
inhibition of phosphofructokinase (PFK), pyruvate kinase (PKM2),
or monocarboxylate transportes (MCT1-4) for the development of
novel anticancer therapies, while compelling biological evidences
encourage the efforts towards the identiﬁcation of viable inhibitors
of other glycolytic targets such as glucose transporters (GLUT) and
hexokinase (HK2).
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